SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing
proprietary cardiovascular diagnostic products, today announced that E.
Ralf Schoenbrunner, Ph.D. has been appointed to the position of senior
vice president of research and early development. Dr. Schoenbrunner has
more than 20 years of experience in the medical device and diagnostic
field including executing multiple successful product development
“Dr. Schoenbrunner has a proven track record of increasing innovation
and productivity within diagnostic companies by planning and directing
all aspects of the organization’s research and development initiatives,”
said Brian Ward, Ph.D., diaDexus’ president and chief executive officer.
“He will play a critical role on our team as we identify and develop our
product pipeline opportunities.”
Most recently, Dr. Schoenbrunner was the vice president of research and
development, molecular diagnostics for Life Technologies Corporation, a
global biotechnology tools company where he helped to build R&D
capabilities for IVD diagnostics. Dr. Schoenbrunner came to Life
Technologies Corporation in 2010 as a key employee through the
acquisition of AcroMetrix where he was the vice president of research
and development. During his tenure at AcroMetrix, a privately held
company and world market leader for nucleic acid testing quality and
control materials, the company launched 30 new products. From 1992 to
2006, Dr. Schoenbrunner held various positions in the research
department at Roche Diagnostics in Switzerland and Roche Molecular
Systems Inc. in California, both world market leaders in diagnostics.
Dr. Schoenbrunner was amongst others responsible for the development of
a fully automated anti-HIV-1/2 assay and development of the first COBAS
TaqMan HIV-1 Test. He studied at University of Regensburg where he got
his Master of Science and also at the University of Edinburgh. He
received his Ph.D. in Physical Biochemistry from the University of
Bayreuth in Germany.
“It’s an exciting time to join the diaDexus team as they execute on the
goal of creating a robust product pipeline,” Dr. Schoenbrunner said. “I
look forward to being an active part of the team that identifies,
develops and commercializes new cardiovascular products.”
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and
commercializes proprietary cardiovascular diagnostic products addressing
unmet needs in cardiovascular disease. The company's PLAC® Test ELISA
Kit is the only blood test cleared by the FDA to aid in predicting risk
for both coronary heart disease and ischemic stroke associated with
atherosclerosis, the #1 and #3 causes of death, respectively, in the
United States. The company's PLAC® Test for Lp-PLA2 Activity,
a CE-marked test, is an indicator of atherosclerotic cardiovascular
disease, the #1 cause of death in Europe. diaDexus is ISO 13485
certified and is manufacturing the PLAC Test for Lp-PLA2
Activity on-site. For more information, please visit the company's
website at www.diaDexus.com.
Brian E. Ward, Ph.D., 650-246-6400
Viret, Ph.D., 650-246-6400
Joey Fleury, 415-946-1090
Source: diaDexus, Inc.